Compare American Well Corp (AMWL) vs Freeport-McMoRan Inc (FCX) Price & Performance

AMWL trades at $12.94, down 0.38% with a bullish technical signal. The company shows improving fundamentals with three consecutive quarterly earnings beats and narrowing losses. Revenue declined to $249.33M in 2025 but net losses improved from -$270M to -$95.70M. Recent news highlights Amwell's strategic developments including a Department of Defense contract and leadership changes at Amazon's healthcare unit.

While AMWL shows operational improvement with reduced cash burn and earnings momentum, the stock faces challenges from declining revenue and persistent losses. Analyst consensus leans cautious with 67% hold ratings. Key risks include execution on profitability targets and competitive pressures in telehealth. The path to cash-flow breakeven in Q4 2026 remains critical for valuation upside.

FCX trades at $66.83, down 2.98% on the day, but maintains a bullish technical trend with strong analyst support. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 expected at $0.72 EPS. Revenue remains stable around $25.9B, while net income margin improved to 11.38% in 2026. Recent news highlights operational challenges like lower copper volumes but also growth initiatives at Grasberg and Bagdad.

The outlook is positive with a consensus price target of $73.85, implying ~10% upside. Key opportunities include exposure to high copper prices and expansion projects, while risks involve production volatility, cost pressures, and reliance on commodity cycles. The stock's valuation appears elevated with a P/E of 33.93, requiring sustained earnings growth to justify further gains.